SCHEMBL283936

SCHEMBL283936

Fc1ccc(C(F)(F)F)cc1Br

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
IDO1 P14902 3/20 0.44
PDE2A O00408 3/20 0.41
MPL P40238 2/20 0.40
PTPN5 P54829 1/20 0.39
ORAI1 Q96D31 1/20 0.38
ORAI2 Q96SN7 1/20 0.38
ORAI3 Q9BRQ5 1/20 0.38
TRPV6 Q9H1D0 1/20 0.38
TRPA1 O75762 1/20 0.38
TDO2 P48775 1/20 0.38
TSHR P16473 2/20 0.37
RXRA P19793 1/20 0.37
GRIN1 Q05586 1/20 0.37
GRIN2B Q13224 1/20 0.37
MAPK1 P28482 1/20 0.37
MEN1 O00255 1/20 0.37
KMT2A Q03164 1/20 0.37
CES2 O00748 2/20 0.36
L3MBTL1 Q9Y468 1/20 0.36
TAS2R14 Q9NYV8 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29762963 1.00 IDO1 (0.44) IDO1PDE2AMPLPTPN5ORAI1
SCHEMBL31550192 0.82 ALOX15 (0.36) IDO1PDE2ATSHRRXRAGRIN1
SCHEMBL607667 0.81 PDE2A (0.46) IDO1PDE2AMPLPTPN5TSHR
SCHEMBL29453079 0.81 PDE2A (0.46) IDO1PDE2AMPLPTPN5TSHR
SCHEMBL29637726 0.80 PTPN5 (0.41) PTPN5TSHRMAPK1MEN1KMT2A
SCHEMBL7863398 0.80 PTPN5 (0.41) PTPN5TSHRMAPK1MEN1KMT2A
SCHEMBL419718 0.79 ALDH1A1 (0.41) TSHRMEN1KMT2AL3MBTL1
SCHEMBL30104741 0.79 ALDH1A1 (0.41) TSHRMEN1KMT2AL3MBTL1
Hydrochloric Acid SCHEMBL12614768 0.79 PDE2A (0.39) IDO1PDE2AMPLPTPN5TDO2
SCHEMBL2147584 0.77 PDE2A (0.50) IDO1PDE2AMPLPTPN5TRPA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 336 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3543319-A1 METHOD OF MARKING HYDROCARBON LIQUIDS Johnson Matthey Public Limited Company (GB) 2019-09-25 EP claimed
US-20140120626-A1 METHOD OF MARKING HYDROCARBON LIQUIDS JOHNSON MATTHEY PUBLIC LIMITED COMPANY (GB) 2014-05-01 US claimed
EP-2707465-A1 METHOD OF MARKING HYDROCARBON LIQUIDS Johnson Matthey Public Limited Company (GB) 2014-03-19 EP claimed
WO-2012153132-A1 METHOD OF MARKING HYDROCARBON LIQUIDS JOHNSON MATTHEY PUBLIC LIMITED COMPANY (GB) 2012-11-15 WO claimed
US-4155940-A M-Bromo-benzotrifluorides BAYER AKTIENGESELLSCHAFT (DE) 1979-05-22 US claimed
US-12509987-B2 Continuous characterization and communication of chemical tracer Patina IP LLC (US) 2025-12-30 US disclosed
US-20250388585-A1 PRMT5 INHIBITORS AND USES THEREOF GILEAD SCIENCES INC (US) 2025-12-25 US disclosed
US-12448388-B2 PRMT5 inhibitors and uses thereof GILEAD SCIENCES, INC. (US) 2025-10-21 US disclosed
US-12441703-B2 Carboxamides as modulators of sodium channels VERTEX PHARMACEUTICALS INCORPORATED (US) 2025-10-14 US disclosed
EP-4267574-B1 6-HETEROARYLOXY BENZIMIDAZOLES AND AZABENZIMIDAZOLES AS JAK2 INHIBITORS AJAX THERAPEUTICS INC (US) 2025-04-23 EP disclosed
US-20250099448-A1 HETEROCYCLIC COMPOUNDS HOFFMANN-LA ROCHE INC. (US) 2025-03-27 US disclosed
EP-4469446-A1 NEW HETEROCYCLIC COMPOUNDS F. Hoffmann-La Roche AG (CH) 2024-12-04 EP disclosed
EP-0742010-A2 Benzoquinolin-3-ones to inhibit bone loss ELI LILLY AND COMPANY (US) 1996-11-13 EP disclosed
EP-0733365-A2 Use of benzoquinolin-3-ones for the treatment and prevention of prostatic cancer ELI LILLY AND COMPANY (US) 1996-09-25 EP disclosed
US-5550134-A ADMINISTERING TO A MAMMAL FROM A SERIES OF BENZOQUINOLIN-3-ONE COMPOUNDS ELI LILLY AND COMPANY (US) 1996-08-27 US disclosed
WO-1996023783-A1 INDOLE DERIVATIVES AS 5-HT RECEPTOR ANTAGONIST SMITHKLINE BEECHAM PLC (GB) 1996-08-08 WO disclosed
EP-0493650-A1 Fluorinated acetylene-containing aromatic amines and diamines National Starch and Chemical Investment Holding Corporation (US) 1992-07-08 EP disclosed
US-5107026-A Fluorinated acetylene-containing aromatic amines and diamines NATIONAL STARCH AND CHEMICAL INVESTMENT HOLDING CORPORATION (US) 1992-04-21 US disclosed
US-4155940-A M-Bromo-benzotrifluorides BAYER AKTIENGESELLSCHAFT (DE) 1979-05-22 US disclosed
US-4155940-A M-Bromo-benzotrifluorides BAYER AKTIENGESELLSCHAFT (DE) 1979-05-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250388585-A1 PRMT5 INHIBITORS AND USES THEREOF PRMT1, PRMT5, PRMT6 IDO1 2735/4885PDE2A 1640/4885MPL 3935/4885
US-12448388-B2 PRMT5 inhibitors and uses thereof PRMT5, PRMT1, PRMT9 IDO1 2821/4885PDE2A 856/4885MPL 2323/4885
US-12509987-B2 Continuous characterization and communication of chemical tracer EXOSC10, CD69, FABP3 IDO1 3837/4885PDE2A 2369/4885MPL 3001/4885
US-12441703-B2 Carboxamides as modulators of sodium channels TRPV1, SCN2A, SCN10A IDO1 3851/4885PDE2A 407/4885MPL 4323/4885
US-20250099448-A1 HETEROCYCLIC COMPOUNDS OPRM1, CYP1A1, CYP3A4 IDO1 805/4885PDE2A 1875/4885MPL 2660/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.